Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PLG | P00747 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | PLAT | P00750 | 2/20 | 0.32 |
| ▸ | KLK1 | P06870 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 3/20 | 0.31 |
| ▸ | BACE1 | P56817 | 3/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25138933 | 0.86 | NLRP3 (0.39) | NLRP3CNR2CNR1 | |
| SCHEMBL20938130 | 0.82 | PRMT5 (0.34) | NLRP3CNR2CNR1F2PLG | |
| SCHEMBL20681557 | 0.77 | NLRP3 (0.39) | NLRP3 | |
| SCHEMBL30791030 | 0.77 | NLRP3 (0.39) | NLRP3 | |
| SCHEMBL25139056 | 0.77 | NLRP3 (0.35) | NLRP3 | |
| SCHEMBL29178966 | 0.76 | CNR1 (0.32) | CNR2CNR1F2PLGPLAU | |
| SCHEMBL29178967 | 0.76 | F2 (0.31) | CNR2CNR1F2PLGPLAU | |
| SCHEMBL20698736 | 0.76 | NLRP3 (0.40) | NLRP3 | |
| SCHEMBL25139105 | 0.74 | NLRP3 (0.34) | NLRP3 | |
| SCHEMBL25139228 | 0.72 | NLRP3 (0.38) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658538-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019023145-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |